developed the ribozyme − SNA architecture for targeting O6 -methylguanine-DNA methyltransferase (MGMT), which is a DNA repair protein enzyme associated with chemotherapeutic resistance (temozolomide [TMZ] resistance) of solid tumors and principally glioblastoma multiforme (GBM). Here, XRCC6P5 is linked to glioblastoma.